VCYTNasdaqServices-Medical LaboratoriesFiscal year ends December 31
VERACYTE, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 31, 2026
$43.80+0.68 (+1.58%)
Close on Oct 19, 2026
- Market cap
- $3.59B
- P/E (TTM)
- 31.3
- Dividend yield
- –
VERACYTE, INC. revenue by segment
By business segment
By product or service
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Testing revenue | $145.66M | $135.09M | $135.83M | $127.76M | $122.26M | $107.31M | $112.15M | $109.54M | $106.97M | $90.30M | $90.39M | $82.01M | 96.9% | +19.1% |
| Other Testing Revenue | $4.50M | $4.20M | $2.50M | $1.50M | $1.80M | $400.00K | $1.80M | $3.10M | $4.00M | $3.00M | $2.30M | $900.00K | 3.0% | +150.0% |
| Product revenue | $3.86M | $3.68M | $3.85M | $3.30M | $3.60M | $3.58M | $3.02M | $3.19M | $3.91M | $3.54M | $3.67M | $4.02M | 2.6% | +7.2% |
| Biopharmaceutical and other revenue | $802.00K | $301.00K | $962.00K | $815.00K | $4.30M | $3.58M | $3.46M | $3.14M | $3.55M | $3.00M | $4.15M | $4.08M | 0.5% | -81.4% |
| Biopharmaceutical revenue | $802.00K | $301.00K | $963.00K | $646.00K | $2.63M | $2.30M | $1.19M | $2.04M | $1.70M | $953.00K | $3.28M | $2.83M | 0.5% | -69.5% |
| Contract manufacturing and testing | $0 | $0 | – | $169.00K | $1.67M | $1.29M | $2.27M | $1.10M | $1.85M | $2.05M | $866.00K | $1.24M | 0.0% | -100.0% |
By region
From the segment and revenue-disaggregation notes of Veracyte's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.